ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
In 1982, at the age of 31, I was diagnosed with a small-fiber length-dependent sensory peripheral neuropathy. Despite extensive laboratory assessments (including genome sequencing), the cause is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback